Harmony Biosciences Holdings Inc (HRMY)
31.57
-0.12
(-0.38%)
USD |
NASDAQ |
May 03, 16:00
31.58
+0.01
(+0.03%)
After-Hours: 20:00
Harmony Biosciences Holdings Gross Profit Margin (Quarterly): 82.22% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 82.22% |
| December 31, 2023 | 74.38% |
| September 30, 2023 | 79.85% |
| June 30, 2023 | 81.37% |
| March 31, 2023 | 82.56% |
| December 31, 2022 | 79.05% |
| September 30, 2022 | 80.41% |
| June 30, 2022 | 82.32% |
| March 31, 2022 | 82.75% |
| Date | Value |
|---|---|
| December 31, 2021 | 80.47% |
| September 30, 2021 | 81.91% |
| June 30, 2021 | 82.81% |
| March 31, 2021 | 82.56% |
| December 31, 2020 | 82.38% |
| September 30, 2020 | 82.70% |
| June 30, 2020 | 83.01% |
| March 31, 2020 | 82.49% |
| December 31, 2019 | 73.69% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
73.69%
Minimum
Dec 2019
83.01%
Maximum
Jun 2020
80.94%
Average
82.27%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Amylyx Pharmaceuticals Inc | 91.37% |
| Exelixis Inc | 95.00% |
| Insmed Inc | 77.96% |
| Ultragenyx Pharmaceutical Inc | 90.54% |
| Immunic Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 28.78% |
| Return on Assets | 17.60% |
| Return on Invested Capital | 20.52% |
| Profit Margin (Quarterly) | 24.79% |
| Operating Margin (Quarterly) | 33.65% |
| Return on Net Operating Assets | 60.36% |